Global In Vivo CRO Market Size, Share & Trends: 2019 to 2026 – ResearchAndMarkets.com

April 11, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “In
vivo CRO Market Size, Share & Trends Analysis Report By Product Type, By
GLP Type, By Indication (Diabetes, Obesity, Autoimmune/Inflammatory, CNS
Conditions), And Segment Forecasts, 2019 – 2026”
report has
been added to ResearchAndMarkets.com’s offering.

The global in vivo CRO market is anticipated to reach USD 5.81 billion
by 2026, according to this report. It is expected to expand at a CAGR of
8.5% during the forecast period.

Increasing focus on core competencies by the pharmaceutical players
coupled with economic efficiency offered for outsourcing is expected to
boost the demand.

In Addition, the CROs are equipped with a competent workforce capable of
performing a diverse number of tasks along with being well-versed
through regulatory requirements. Also, the pressure from the increasing
competition owing to rapid growth of generics, patent expirations, and
introduction of biosimilar equivalents are encouraging pharmaceutical
companies to take the aid of such organizations.

Increasing mergers and collaborations have propelled the value of
pharmaceutical outsourcing with major industry contributors expanding
into developing regions. The year 2015 experienced high valued
transactions as a result of LabCorp acquiring Covance for USD 5.5
billion and the Chinese Private Equity Group acquiring WuXi for USD 3.3
billion. The patent cliff, high research and development cost involved,
and globalization in the clinical trial process has driven the

Further key findings from the report suggest:

  • Rodent based In vivo CRO led the market in 2018 and is anticipated to
    remain dominant throughout the forecast period. Mice is the most used
    animal for preclinical evaluation and accounted for almost 76% of the
    market share in 2018
  • Based on indication, oncology held the largest market share in 2018,
    attributed to the increasing number of cancer cases and focus of
    pharmaceutical players on introducing novel drug treatments with fewer
    side-effects
  • North America led the global In vivo CRO market in 2018 owing to the
    presence of technologically advanced CROs
  • Asia Pacific is anticipated to register the fastest CAGR over the
    forecast period. Constantly improving healthcare infrastructure, huge
    patient base, presence of untapped opportunities, and economic
    development, are some factors responsible for the rapid growth
  • Some of the key market players include Pharmaceutical Product
    Development, LLC (PPD); IQVIA; American Preclinical Services, LLC.;
    Charles River Laboratories; Parexel International Corporation; ICON
    Plc; Covance Inc.; Theorem Clinical research; inVentiv Health; WuXi
    AppTec, Inc.; American Preclinical Services, LLC.; and Evotec (US),
    Inc. Partnership and mergers and acquisitions are the key strategic
    undertakings by these players

Companies Mentioned

  • Quintiles
  • Charles River Laboratories
  • Icon PLC
  • Covance Inc.
  • Parexel International
  • Pharmaceutical Product Development
  • Theorem Clinical Research
  • Inventiv Health
  • Wuxi Apptec Inc.
  • American Preclinical Services
  • Evotec (US) Inc.

Key Topics Covered

Chapter 1 Report Scope

1.1 Segment Market Scope

1.2 Regional Scope

Chapter 2 Methodology

2.1 Research Methodology

2.2 Information Or Data Analysis

2.3 Market Formulation & Validation

2.4 Region Wise Market Calculation

2.5 Region Based Segment Share Calculation

2.6 Model Details

2.7 List Of Secondary Sources

2.8 List Of Primary Sources

2.9 List Of Abbreviations

Chapter 3 Objectives

3.1 Objective – 1:

3.2 Objective – 2:

3.3 Objective – 3:

3.4 Objective – 4:

Chapter 4 Executive Summary

4.1 Market Outlook

4.2 Segment Outlook

4.3 Competitive Insights

Chapter 5 In Vivo CRO Market: Variables, Trends & Scope

5.1 Market Lineage Outlook

5.2 Penetration & Growth Prospect Mapping

5.3 Product Pipeline Analysis, By Stage

5.4 User Perspective Analysis

5.5 List Of Key End-Users, By Region / By Product / By Country

5.6 Regulatory Framework

5.7 Market Variable Analysis

5.8 In Vivo CRO Market: Analysis Tools

Chapter 6 In Vivo CRO Market: Services Segment Analysis

6.1 In Vivo CRO Market: Definition & Scope

6.2 In Vivo CRO Market: Segment Dashboard

6.3 In Vivo CRO Market: Market Share Analysis, 2018 & 2026

6.4 Rodent Based In Vivo GLP Type

6.5 Non-Rodent Based In Vivo GLP Type

Chapter 7 In Vivo CRO Market: Type Segment Analysis

7.1 In Vivo CRO Market: Definition & Scope

7.2 In Vivo CRO Market: Segment Dashboard

7.3 In Vivo CRO Market: Market Share Analysis, 2018 & 2026

7.4 Non GLP

7.5 GLP Toxicology

Chapter 8 In Vivo CRO Market: Indication Segment Analysis

8.1 In Vivo CRO Market: Definition & Scope

8.2 In Vivo CRO Market: Segment Dashboard

8.3 In Vivo CRO Market: Market Share Analysis, 2018 & 2026

8.4 Autoimmune/ Inflammatory Conditions

8.5 Pain Management

8.6 Oncology

8.7 CNS Conditions

8.8 Diabetes

8.9 Obesity

8.10 Others

Chapter 9 In Vivo CRO Market: Regional Analysis

9.1 In Vivo CRO Market: Definition & Scope

9.2 Regional Market Snapshot

9.3 Regional Market Share And Leading Players, 2018

9.4 SWOT Analysis, By Factor (Political & Legal, Economic And
Technological)

9.5 In Vivo CRO Market: Market Share Analysis, 2018 & 2026

9.6 North America

9.7 Europe

9.8 Asia Pacific

9.9 Latin America

9.10 MEA

Chapter 10 Competitive Analysis

10.1 Recent Developments & Impact Analysis, By Key Market Participants

10.2 Company/Competition Categorization (Key Innovators, Market Leaders,
Emerging Players)

10.3 Vendor Landscape

10.4 Public Companies

10.5 Private Companies

10.6 Supplier Ranking

Chapter 11 Company Profiles

11.1 Strategic Framework

Chapter 12 KOL Commentary

Chapter 13 Recommendation

For more information about this report visit https://www.researchandmarkets.com/r/dfzio7

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]

For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related
Topics: Drug
Discovery